By Counterforce Health Team in Ocrevus (ocrelizumab) —

How to Renew Ocrevus (Ocrelizumab) Approval with Humana in New Jersey: 2025 Renewal Requirements and Timeline

Answer Box: Renewing Ocrevus (Ocrelizumab) with Humana in New Jersey

Humana requires prior authorization renewal for Ocrevus (ocrelizumab) every 6-12 months, with no grace period for continuation coverage. Start your renewal 30-45 days before your current authorization expires to avoid treatment gaps. Submit updated medical necessity documentation through your provider's Humana portal, including recent MRI results, clinical progress notes, and evidence of ongoing benefit. If denied, you have 60 days to appeal through Medicare Advantage procedures (not New Jersey's IHCAP program, which doesn't cover federal Medicare plans).

First step today: Contact your neurologist's office to verify your current authorization expiration date and schedule renewal submission.

Table of Contents

  1. Renewal Triggers: When to Start the Process
  2. Evidence Update Requirements
  3. Complete Renewal Documentation Packet
  4. Submission Timeline and Decision Windows
  5. If Your Authorization Lapses
  6. Annual Plan Changes to Monitor
  7. Personal Renewal Tracker Template
  8. Appeals Process for Denials
  9. FAQ: Common Renewal Questions

Renewal Triggers: When to Start the Process

Standard Renewal Windows

Humana typically approves Ocrevus (ocrelizumab) for 6-12 month periods, with most initial approvals lasting 6 months and subsequent renewals extending to 12 months if you demonstrate stable response. Unlike some insurers, Humana provides no grace period for continuation coverage beyond the authorization end date.

Start your renewal process 30-45 days early because:

  • Standard prior authorization decisions take 5-14 business days
  • Additional documentation requests can add 7-10 days
  • Scheduling your next infusion requires active authorization

Signs You Should Start Early

Begin renewal preparation immediately if you experience:

  • New MS symptoms or functional decline
  • Breakthrough disease activity on recent MRI
  • Serious infections or other safety concerns
  • Lab abnormalities (low immunoglobulins, liver enzymes)
  • Insurance plan changes for the upcoming year

These situations may require additional documentation or trigger utilization management reviews that extend processing time.

Evidence Update Requirements

Documenting Treatment Response

Humana's renewal criteria require evidence of "beneficial clinical response" defined as:

For Relapsing MS:

  • Stable or reduced annualized relapse rate
  • No clear disability progression (stable EDSS)
  • Stable or improved MRI activity (fewer new T2 or gadolinium-enhancing lesions)

For Primary Progressive MS:

  • Maintenance of ambulation (typically EDSS < 7.5)
  • No rapid disability progression
  • Stable functional status

Required Clinical Documentation

Your neurologist must provide updated records including:

Documentation Type Required Elements Frequency
Progress Notes Current symptoms, functional status, EDSS score, medication adherence Most recent visit (within 90 days)
MRI Results Brain ± spine MRI with comparison to baseline; new T2 or Gd+ lesions Annual or per protocol
Laboratory Results CBC, comprehensive metabolic panel, immunoglobulin levels Before each infusion or annually
Safety Assessment Infection history, malignancy screening, vaccination status Ongoing documentation

Adverse Events Documentation

Critical safety concerns that may affect renewal:

  • Serious infections requiring hospitalization
  • Opportunistic infections
  • Significant hypogammaglobulinemia (IgG < 400 mg/dL)
  • New malignancies
  • Severe infusion reactions

Document the clinical decision to continue despite any adverse events, including risk-benefit analysis and monitoring plan.

Complete Renewal Documentation Packet

Core Required Documents

Submit through your provider's Humana portal or designated submission method:

  1. Updated Prior Authorization Form
    • Patient demographics and insurance information
    • Current diagnosis codes (G35 for MS)
    • Requested therapy details and administration schedule
  2. Medical Necessity Letter Update
    • Brief clinical summary since last approval
    • Treatment response assessment
    • Justification for continuation
    • Any changes in clinical status or treatment plan
  3. Clinical Progress Notes
    • Most recent neurologist visit (within 90 days)
    • Functional assessment and EDSS documentation
    • Medication adherence and tolerability
  4. Recent MRI Report
    • Comparison to baseline and prior studies
    • Assessment of disease activity
    • Radiologist interpretation of treatment response
  5. Laboratory Results
    • Complete blood count with differential
    • Comprehensive metabolic panel
    • Immunoglobulin levels (IgG, IgM, IgA)
    • Any additional safety labs as indicated

Medical Necessity Letter Structure

Your provider's letter should address:

Clinical Status:

  • Current MS phenotype and disease course
  • Functional status and disability level
  • Symptom control and quality of life

Treatment Response:

  • Relapse rate comparison (pre- vs. on-treatment)
  • MRI activity assessment
  • Disability progression analysis

Safety Profile:

  • Infection history and current status
  • Laboratory monitoring results
  • Risk mitigation strategies

Continuation Rationale:

  • Why Ocrevus remains appropriate
  • Alternative therapy considerations
  • Treatment goals and monitoring plan

Submission Timeline and Decision Windows

Optimal Submission Schedule

Timeline Action Required Responsible Party
45 days before expiration Schedule renewal visit with neurologist Patient
30 days before expiration Complete clinical assessment and MRI if due Provider
21 days before expiration Submit complete renewal packet Provider
14 days before expiration Follow up on submission status Provider/Patient
7 days before expiration Confirm approval or initiate expedited review Provider

Humana Decision Timeframes

  • Standard review: 5-14 business days from complete submission
  • Expedited review: 72 hours (requires clinical urgency documentation)
  • Additional information requests: Up to 14 additional days
Tip: Use Humana's provider portal tracking system to monitor your submission status and respond quickly to any documentation requests.

If Your Authorization Lapses

Immediate Steps

If your Ocrevus authorization expires before renewal approval:

  1. Contact Humana immediately to request expedited review
  2. Document clinical urgency - risk of relapse or disease progression
  3. Request retroactive authorization for any missed doses
  4. Consider bridge therapy options (discuss with neurologist)

Bridge Therapy Considerations

While awaiting renewed authorization, your neurologist may consider short-term alternatives covered under your Part D benefit:

Potential Part D Bridge Options:

  • Oral corticosteroids for acute symptoms
  • Generic disease-modifying therapies (if clinically appropriate)
  • Symptomatic medications for MS-related symptoms

Important: Bridge therapy decisions should only be made by your neurologist based on your specific clinical situation and risk profile.

Emergency Infusion Coverage

For urgent clinical situations, your provider can:

  • Submit a same-day expedited authorization request
  • Provide clinical documentation of immediate medical necessity
  • Request retroactive coverage for emergency treatment

Annual Plan Changes to Monitor

2025 Formulary Updates

Humana's 2025 formulary changes may affect your Ocrevus coverage:

Monitor for:

  • Changes in prior authorization requirements
  • New step therapy protocols
  • Formulary tier adjustments
  • Site of care restrictions

Plan Design Shifts

Medicare Advantage changes for 2025:

  • Part B specialty drug cost-sharing modifications
  • Provider network updates
  • Preferred infusion center designations
  • Appeals process refinements
Note: Review your Annual Notice of Changes (ANOC) carefully each fall and discuss any coverage modifications with your neurologist.

Personal Renewal Tracker Template

Key Information to Track

Current Authorization Details:

  • Authorization number: ________________
  • Approval period: _______ to _______
  • Approved doses/frequency: ________________
  • Next infusion date: ________________

Renewal Preparation Checklist:

  • Neurologist appointment scheduled (45 days prior)
  • MRI scheduled if due (30 days prior)
  • Lab work completed (21 days prior)
  • Renewal packet submitted (21 days prior)
  • Approval confirmation received

Important Contacts:

  • Neurologist office: ________________
  • Humana provider services: ________________
  • Infusion center: ________________
  • Patient advocate (if applicable): ________________

Appeals Process for Denials

Medicare Advantage Appeal Levels

Since Humana Medicare Advantage is a federal program, appeals follow Medicare procedures, not New Jersey's IHCAP program:

Level 1: Plan Reconsideration

  • Deadline: 60 days from denial notice
  • Timeline: 7-14 days for coverage determinations
  • Expedited option: 72 hours if delay risks health

Level 2: Independent Review Entity (IRE)

  • Deadline: 60 days from Level 1 denial
  • Timeline: Similar to Level 1 timeframes
  • Binding decision on Medicare coverage rules

Level 3+: Administrative Law Judge and beyond

  • Available if dollar threshold met
  • Formal hearing process
  • Further appeal levels available

Strengthening Your Appeal

Include in your appeal packet:

  • Updated medical necessity letter addressing specific denial reasons
  • Published evidence supporting Ocrevus use for your MS phenotype
  • Treatment failure documentation for any required step therapy alternatives
  • Functional decline evidence if treatment is interrupted

For assistance with Medicare appeals in New Jersey, contact the State Health Insurance Assistance Program (SHIP) at 1-800-792-8820.

FAQ: Common Renewal Questions

Q: How long does Humana take to process Ocrevus renewals? A: Standard renewals take 5-14 business days from complete submission. Expedited reviews are completed within 72 hours when clinical urgency is documented.

Q: Can I get a longer authorization period after my first renewal? A: Yes, many patients receive 12-month renewals after demonstrating stable response during their initial 6-month authorization period.

Q: What if my MRI shows new lesions? A: New MRI activity doesn't automatically disqualify renewal. Your neurologist should document the clinical significance and whether Ocrevus remains the optimal therapy.

Q: Does Humana require step therapy for Ocrevus renewals? A: Step therapy requirements typically apply to initial approvals. Renewals focus on demonstrating ongoing benefit and safety rather than trying alternative therapies.

Q: What happens if I switch Humana plans during the year? A: You may need to restart the prior authorization process with your new plan, even if it's another Humana product. Start this process immediately upon plan changes.

Counterforce Health helps patients navigate complex insurance approvals by turning denials into targeted, evidence-backed appeals. Our platform analyzes your specific denial reasons and drafts point-by-point rebuttals aligned to your plan's own coverage rules, significantly improving approval rates for specialty medications like Ocrevus. Learn more about our coverage advocacy services.

Sources & Further Reading

Disclaimer: This information is for educational purposes only and does not constitute medical or legal advice. Always consult with your healthcare provider regarding treatment decisions and your insurance company for coverage details specific to your plan. Coverage policies and requirements may change; verify current information with official sources.

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.